Table 3.
Results of univariate and multivariate analysis for overall survival with FOLFIRI
| Death | Univariate analysis | Multivariate analysis | |||||
| Yes/no (49/14) | HR | 95% CI | P value | HR | 95% CI | P value | |
| Primary tumor location1 | 0.306 | ||||||
| Body or tail | 16/2 | 1 | |||||
| Head | 25/7 | 0.717 | (0.380-1.355) | ||||
| Stage at the diagnosis | 0.754 | 0.644 | |||||
| Resectable | 20/4 | 1 | 1 | ||||
| Locally advanced | 13/6 | 1.012 | (0.497-2.058) | 0.790 | (0.346-1.806) | ||
| Metastatic | 16/4 | 1.271 | (0.643-2.515) | 1.205 | (0.577-2.514) | ||
| Previous surgery | 0.203 | ||||||
| No | 31/9 | 1 | |||||
| Yes | 18/5 | 0.676 | (0.370-1.236) | ||||
| Previous radiotherapy | 0.916 | 0.935 | |||||
| No | 38/9 | 1 | 1 | ||||
| Yes | 11/5 | 0.964 | (0.491-1.894) | 0.965 | (0.412-2.260) | ||
| Number of previous chemotherapy lines | 0.102 | 0.171 | |||||
| 1 | 14/5 | 1 | 1 | ||||
| 2 | 30/9 | 1.234 | (0.649-2.346) | 1.197 | (0.564-2.538) | ||
| 3 | 5/0 | 3.188 | (1.090-9.326) | 2.945 | (0.930-9.324) | ||
| Liver metastases | 0.599 | 0.957 | |||||
| No | 9/3 | 1 | 1 | ||||
| Yes | 40/11 | 1.217 | (0.586-2.528) | 0.978 | (0.444-2.159) | ||
| WHO performance status | 0.004 | 0.004 | |||||
| 0 | 22/5 | 1 | 1 | ||||
| 1 | 18/6 | 1.360 | (0.719-2.573) | 1.284 | (0.650-2.535) | ||
| 2 | 9/3 | 4.003 | (1.770-9.056) | 4.702 | (1.883-11.741) | ||
| Type of FOLFIRI regimen | 0.856 | ||||||
| FOLFIRI-1 | 42/13 | 1 | |||||
| FOLFIRI-3 | 7/1 | 1.083 | (0.458-2.562) | ||||
HR: Hazard ratio; WHO: World Health Organization.
1
Data available in 50 out of 63 cases.